InfluenzaPhase 1NCT07302256
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
A Phase 1 study testing Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine and Phosphate buffer solution (PBS) in people with Influenza, run by Shanghai Institute Of Biological Products at 1 site in China.
Trial summary
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Influenza
- What is being tested?
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine and Phosphate buffer solution (PBS)
- Type of treatment
- Vaccines
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 16 Dec 2025to 31 Aug 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age over 60 years old, gender not limited, and able to provide legal identification;
- Volunteers voluntarily participate in the study and sign an informed consent form;
- Volunteers have the ability to understand research procedures, use thermometers, scales, and fill out diary cards as required, and can participate in all planned follow-up visits.
Who cannot join
- On the day of enrollment, the axillary temperature was ≥ 37.3 ℃;
- Those who have had influenza in the past 6 months or meet the definition of influenza like cases;
- Have received any influenza vaccine within the past 12 months or have planned to receive any influenza vaccine during the study period;
- Allergies to any components of the research vaccine, history of allergic reactions to the use of gentamicin sulfate, history of severe allergies to any vaccine/drug, or history of asthma;
- Suffering from a serious illness that prevents the completion of the entire study; Within 3 days prior to vaccination, there is an acute illness or an acute exacerbation of a chronic disease;
- Have used antipyretic or analgesic drugs or anti allergic drugs within 3 days before vaccination;
Show all 18Show fewer
- Have received any vaccine within 2 weeks prior to vaccination;
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months prior to receiving the experimental vaccine, For example, immunosuppressive doses of glucocorticoids, monoclonal antibodies, thymosin, interferon, etc., or planned to receive such treatment within one month after the first dose of vaccination to full immunization, but local medication is allowed;
- Suffering from congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, or other autoimmune diseases;
- Suffering from serious chronic diseases, serious cardiovascular diseases, such as hypertension that cannot be controlled by drugs, diabetes that cannot be controlled by drugs or has serious complications, liver and kidney diseases, pulmonary edema, malignant tumors, etc;
- Have received blood or blood related products within the past 6 months;
- Individuals with progressive neurological disorders, including a history of seizures, epilepsy, encephalopathy, Guillain Barr é syndrome, psychiatric or family history;
- Have a history of abnormal coagulation function and have been using anticoagulants within 3 weeks before vaccination;
- Patients with splenectomy, functional splenectomy, splenectomy, or other important organ resection or partial resection;
- Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
- Currently or recently planning to participate in other clinical trials;
- Abnormal laboratory test indicators before vaccination;
- Researchers determine any situation that is not suitable for clinical trials.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Danjiangkou Disease Prevention and Control Center
Wuhan, Hubei
Yunbo Pan, 86-15897801799, 2792320450@qq.com
About this study
Official title: A Randomized, Double-blind, Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. The three groups were recruited at a ratio of 1:1:1, and 40 individuals were randomly vaccinated in each group. Each person was injected with one dose of the vaccine into the deltoid muscle of the upper arm. Participants in each study group are required to undergo laboratory indicator tests before and on the 4th day after vaccination.
- Conditions
- Influenza
- Being tested
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine, Phosphate buffer solution (PBS)
- Keywords
- Influenza virus split vaccine, The elderly, Immunogenicity, Safety
- Medical subject headings
- Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Influenza virus split vaccine (0.7mL/vial)Biological
Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each
Influenza virus split vaccineBiological
Influenza virus split vaccine, with a specification of 0.5mL/bottle, containing 15 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each
Phosphate buffer solution (PBS)Biological
PBS, with a specification of 0.5mL/bottle.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Influenza virus split vaccine, with a specification of 0.7mL/bottle Receives: Biological: Influenza virus split vaccine (0.7mL/vial) |
| Control group 1 | Active comparator | Influenza virus split vaccine, with a specification of 0.5mL/bottle Receives: Biological: Influenza virus split vaccine |
| Control group 2 | Placebo comparator | Phosphate buffer solution Receives: Biological: Phosphate buffer solution (PBS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Unsolicited Adverse Events
Other adverse events that occurred among participants within 0-30 days after vaccination, in addition to the solicited adverse events.
Measured: 30 days after vaccination
Solicited Adverse Events (AEs)
Adverse events defined by the protocol that occurred to the participant during 0-7 days after vaccination.
Measured: 7 days after vaccination
Serious Adverse Events (SAE)
That is serious adverse events, any serious adverse events that occurred to the participant during the study period.
Measured: 6 months after vaccination
Secondary outcomes (4)
Seroconversion rate
30 days after vaccination of all participants with the experimental vaccine or control vaccines, the HI antibody seroconversion rate against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.
Measured: 30 days after vaccination
Ratio of ≥1:40
30 days after vaccination of all participants with the experimental vaccine or control vaccines, the ratio of HI antibody titers ≥ 1:40 against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.
Measured: 30 days after vaccination
Geometric mean titer (GMT)
30 days after vaccination of all participants with the experimental vaccine or control vaccines, GMT of HI antibodies against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.
Measured: 30 days after vaccination
Geometric mean increase (GMI)
30 days after vaccination of all participants with the experimental vaccine or control vaccines, GMI of HI antibodies against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.
Measured: 30 days after vaccination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start16 Dec 2025
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfluenzaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Institute Of Biological Products
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yeqing Tong, Principal investigator, Hubei Provincial Center for Disease Control and Prevention
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07302256
- Sponsor's protocol ID
- SIBP-V05-001
- Status last verified
- Dec 2025
- First submitted
- 11 Dec 2025
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
- ClinicalTrials.gov ID
- NCT07302256
- Acronym / sponsor ID
- SIBP-V05-001
- Conditions
- Influenza
- Keywords
- Influenza virus split vaccine, The elderly, Immunogenicity, Safety
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Shanghai Institute Of Biological ProductsIndustry (pharma, biotech, devices)
- Study start
- 16 Dec 2025 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Aug 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. The three groups were recruited at a ratio of 1:1:1, and 40 individuals were randomly vaccinated in each group. Each person was injected with one dose of the vaccine into the deltoid muscle of the upper arm. Participants in each study group are required to undergo laboratory indicator tests before and on the 4th day after vaccination.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Biological: Influenza virus split vaccine (0.7mL/vial)Influenza virus split vaccine, with a specification of 0.7mL/bottle |
| Control group 1 | Active comparator | Biological: Influenza virus split vaccineInfluenza virus split vaccine, with a specification of 0.5mL/bottle |
| Control group 2 | Placebo comparator | Biological: Phosphate buffer solution (PBS)Phosphate buffer solution |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age over 60 years old, gender not limited, and able to provide legal identification;
- Volunteers voluntarily participate in the study and sign an informed consent form;
- Volunteers have the ability to understand research procedures, use thermometers, scales, and fill out diary cards as required, and can participate in all planned follow-up visits.
Key exclusion criteria (18 listed)
- On the day of enrollment, the axillary temperature was ≥ 37.3 ℃;
- Those who have had influenza in the past 6 months or meet the definition of influenza like cases;
- Have received any influenza vaccine within the past 12 months or have planned to receive any influenza vaccine during the study period;
- Allergies to any components of the research vaccine, history of allergic reactions to the use of gentamicin sulfate, history of severe allergies to any vaccine/drug, or history of asthma;
- Suffering from a serious illness that prevents the completion of the entire study; Within 3 days prior to vaccination, there is an acute illness or an acute exacerbation of a chronic disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Influenza virus split vaccine (0.7mL/vial)Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each | Biological | Experimental group |
| Influenza virus split vaccineInfluenza virus split vaccine, with a specification of 0.5mL/bottle, containing 15 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each | Biological | Control group 1 |
| Phosphate buffer solution (PBS)PBS, with a specification of 0.5mL/bottle. | Biological | Control group 2 |
Primary outcome
Unsolicited Adverse Events
Time frame: 30 days after vaccination
Other adverse events that occurred among participants within 0-30 days after vaccination, in addition to the solicited adverse events.
Solicited Adverse Events (AEs)
Time frame: 7 days after vaccination
Adverse events defined by the protocol that occurred to the participant during 0-7 days after vaccination.
Serious Adverse Events (SAE)
Time frame: 6 months after vaccination
That is serious adverse events, any serious adverse events that occurred to the participant during the study period.
4 secondary outcomes
Seroconversion rate
Time frame: 30 days after vaccination
Ratio of ≥1:40
Time frame: 30 days after vaccination
Geometric mean titer (GMT)
Time frame: 30 days after vaccination
Geometric mean increase (GMI)
Time frame: 30 days after vaccination
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Influenza
Not yet recruitingPhase 2/3
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
Influenza, Human
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
Not yet recruiting
Family Physician Nudges for Influenza Vaccination Among Older Adults
Influenza Vaccination
Recruiting
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
COVID-19 Respiratory Infection, Influenza
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yeqing Tong principal investigator
Hubei Provincial Center for Disease Control and Prevention
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine and Phosphate buffer solution (PBS) in people with Influenza, run by Shanghai Institute Of Biological Products at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yang Liu (86-010-65777702, liuyang30@sinopharm.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Unsolicited Adverse Events (time frame: 30 days after vaccination). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.